From: Highly active antiretroviral therapy and hospital readmission: comparison of a matched cohort
Pre-Propensity Score Match | Post-Propensity Score Match | |||||
---|---|---|---|---|---|---|
On HAART N (%) | Not on HAART N (%) | P-value | On HAART N (%) | Not on HAART N (%) | P-value | |
CMV | 27 (7.9) | 15 (2.0) | < 0.01 | 27 (8.2) | 8 (2.4) | < 0.01 |
Candidiasis | 23 (6.7) | 35 (4.7) | 0.17 | 23 (7.0) | 17 (5.1) | 0.33 |
Cryptococcis | 10 (2.9) | 31 (4.2) | 0.31 | 10 (3.0) | 14 (4.2) | 0.41 |
HIV Dementia | 12 (3.5) | 16 (2.2) | 0.19 | 12 (3.6) | 15 (4.5) | 0.56 |
Kaposi's Sarcoma | 30 (8.8) | 24 (3.2) | < 0.01 | 30 (9.1) | 17 (5.1) | 0.05 |
Lymphoma | 17 (5.0) | 20 (2.7) | 0.06 | 17 (5.1) | 14 (4.2) | 0.58 |
MAC | 29 (8.5) | 28 (3.8) | < 0.01 | 29 (8.8) | 12 (3.6) | 0.87 |
PCP | 84 (24.6) | 135 (18.2) | 0.02 | 83 (25.1) | 68 (20.1) | 0.85 |
Pneumonia | 29 (8.5) | 83 (11.2) | 0.17 | 29 (8.8) | 30 (9.1) | 0.89 |
Toxoplasmosis | 6 (1.8) | 8 (1.1) | 0.36 | 6 (1.8) | 3 (0.9) | 0.78 |
Tuberculosis | 8 (2.3) | 27 (3.6) | 0.26 | 8 (2.4) | 10 (3.0) | 0.79 |
Wasting | 24 (7.0) | 36 (4.9) | 0.15 | 24 (7.3) | 19 (5.7) | 0.66 |